2.53
+5.86%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Larimar Therapeutics
From its filings with the US Securities and Exchange Commission
Larimar Therapeutics is based in Bala Cynwyd, Pennsylvania and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker LRMR. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2019, it reported revenue of $0.
We are a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using our novel cell penetrating peptide (“CPP”) technology platform. Our lead product candidate, nomlabofusp, is a subcutaneously administered, recombinant fusion protein intended to deliver frataxin (“FXN”), an essential protein, to the mitochondria of patients with Friedreich's ataxia (“FA”). FA is a rare, progressive, and fatal disease in which patients are unable to produce sufficient FXN due to a genetic abnormality. Currently, there are no treatment options that address the core deficit of FA, low levels of FXN. Nomlabofusp represents the first potential therapy designed to systemically increase FXN levels in patients with FA.
We believe that our CPP platform, which enables a therapeutic molecule to cross a cell membrane in order to reach intracellular targets, also has the potential to enable the treatment of other rare and orphan diseases. We intend to use our proprietary platform to target additional orphan indications characterized by deficiencies in or alterations of intracellular content or activity.
Quoted from its 10-K, filed 19 Mar 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 19 Jun 2014
- Employees
- 71
- Website
- larimartx.com ↗
- Head office
- THREE BALA PLAZA EAST. SUITE 506, BALA CYNWYD, PA, 19004
- Incorporated in
- DE
- Classification
- Pharmaceutical Preparations
- Filer status
- Non-accelerated filer<br>Smaller reporting company
Leadership
Pay as last reported
- Mr. Joseph TruittIndependent Chairman of the Board$185,491
- Dr. Carole Ben-MaimonPresident, Chief Executive Officer, Director, since 2020$2.5m
- Mr. Michael CelanoChief Financial Officer, Secretary$1.4m
- Dr. Russell ClaytonChief Medical Officer
- Dr. Gopi ShankarChief Development Officer$1.2m
- Mr. Thomas HamiltonIndependent Director$149,241
- Mr. Jonathan LeffIndependent Director$150,491
- Dr. Jeffrey ShermanIndependent Director$141,741
- Mr. Frank ThomasIndependent Director$157,991
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 53
- Environment
- 54
- Social
- 81
- Governance
- 25
- Women in the workforce
- 53%
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Innovative Therapies: Larimar Therapeutics Inc is known for its innovative therapies that have the potential to address currently unmet medical needs.
- Strong Scientific Expertise: The company has a team of highly skilled scientists and researchers who are well-versed in the field of pharmaceuticals and gene therapy.
- Intellectual Property: Larimar Therapeutics Inc possesses a strong portfolio of intellectual property, including patents and proprietary technology, which provides a significant competitive advantage.
Weaknesses
- Limited Financial Resources: The company may face challenges in funding its research and development activities due to its limited financial resources.
- Lack of Market Presence: Larimar Therapeutics Inc is a relatively new entrant in the market and has yet to establish a strong market presence and brand recognition.
- Regulatory Challenges: The pharmaceutical industry is highly regulated, and compliance with strict regulatory requirements may pose a challenge for the company.
Opportunities
- Growing Demand for Gene Therapies: With the increasing prevalence of genetic disorders, there is a growing demand for innovative gene therapies, which presents a significant opportunity for Larimar Therapeutics Inc.
- Partnerships and Collaborations: The company can explore strategic partnerships and collaborations with other pharmaceutical companies or research institutions to expand its research capabilities and market reach.
- Emerging Markets: Larimar Therapeutics Inc can consider expanding its operations into emerging markets where there is a rising need for advanced therapies.
Threats
- Intense Competition: The pharmaceutical industry is highly competitive, and Larimar Therapeutics Inc may face intense competition from established players and emerging biotech companies.
- Legal and Regulatory Risks: Changes in regulations or legal challenges related to intellectual property rights or drug approvals can pose significant risks to the company's operations.
- Technological Advancements: Rapid advancements in technology may lead to the development of alternative treatment options, which could potentially diminish the market potential for Larimar Therapeutics Inc's therapies.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.